drugset / Trial / NCT00809289

Phase 1 Thorough QT (TQT) Study in Young Healthy Volunteers

NCT00809289

Phase 1 Completed 40 enrolled Pfizer
RandomizedCrossoverDouble-blindBasic science

Summary

This Phase 1 study will assess the effects of esreboxetine on the heart. In particular the effects on a specific electrocardiogram (ECG) measurement called QTc will be measured.

Timeline

Start
2008-12
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg Oral
Subject [S,S]-Reboxetine Unknown 10 mg

Indications